CZY43

CZY43 (compound 6d) (1-3 μM; 8 h) potently degrades HER3 in breast cancer SKBR3 cells. After 8 h of treatment, the degradation rate reaches 67% at 1 μM and 96% at 3 μM^[1].
CZY43 (0-2000 nM; 0-24 h) induces dose- and time-dependent degradation of HER3 in breast cancer SKBR3 cells, and effectively reduces HER3 protein levels in breast cancer MDA-MB-453 cells and non-small cell lung cancer A549 cells^[1].
CZY43 (125 nM-2000 nM; 8 h) potently inhibits the HER3-dependent signaling pathway in breast cancer SKBR3 cells by reducing the protein levels of HER3 and phosphorylated AKT in a dose-dependent manner^[1].
CZY43 potently inhibits the proliferation of breast cancer SKBR3 cells with an IC₅₀ of 0.53 μM, and reduces the adhesion capacity of SKBR3 cells in a dose-dependent manner^[1].
CZY43 (1 μM; 8 h) induces HER3 degradation in breast cancer SKBR3 cells via autophagy, as evidenced by enhanced Hsp90-HER3 binding, increased HER3 ubiquitination, reversal of this degradation process by Chloroquine (HY-17589A), and dose-dependent activation of LC3B^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.